Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy. The molecular mechanisms determining HCM phenotypes are incompletely understood. Myocardial biopsies were obtained from a group of patients with obstructive HCM (n = 23) selected for surgical myectomy and from 9 unused donor hearts (controls). A subset of tissue-abundant myectomy samples from HCM (n = 10) and controls (n = 6) was submitted to laser-capture microdissection to isolate cardiomyocytes. We investigated the relationship among clinical phenotype, cardiac myosin proteins (MyHC6, MyHC7, and MyHC7b) measured by optimized label-free mass spectrometry, the relative genes (MYH7, MYH7B and MYLC2), and the MyomiR network (myosin-encoded microRNA (miRs) and long-noncoding RNAs (Mhrt)) measured using RNA sequencing and RT-qPCR. MyHC6 was lower in HCM vs. controls, whilst MyHC7, MyHC7b, and MyLC2 were comparable. MYH7, MYH7B, and MYLC2 were higher in HCM whilst MYH6, miR-208a, miR-208b, miR-499 were comparable in HCM and controls. These results are compatible with defective transcription by active genes in HCM. Mhrt and two miR-499-target genes, SOX6 and PTBP3, were upregulated in HCM. The presence of HCM-associated mutations correlated with PTBP3 in myectomies and with SOX6 in cardiomyocytes. Additionally, iPSC-derived cardiomyocytes, transiently transfected with either miR-208a or miR-499, demonstrated a time-dependent relationship between MyomiRs and myosin genes. The transfection end-stage pattern was at least in part similar to findings in HCM myectomies. These data support uncoupling between myosin protein/genes and a modulatory role for the myosin/MyomiR network in the HCM myocardium, possibly contributing to phenotypic diversity and providing putative therapeutic targets.

Plasma Extracellular Vesicles as Liquid Biopsy to Unravel the Molecular Mechanisms of Cardiac Reverse Remodeling Following Resynchronization Therapy?

“…miRNAs act mainly by regulating gene expression at the post-transcriptional level, either by directing their target mRNAs to be degraded or by inhibiting their translation. Several studies have shown that miRNAs are key players in heart remodeling, including hypertrophy and fibrosis, in in vivo disease models and in vitro [ 39 , 40 , 41 , 42 ]. Overexpression of miRNA-195 leads to cardiac pathological hypertrophy and heart failure in mice [ 43 ].…”

The Aging Heart: A Molecular and Clinical Challenge

“…Genetic HCM and DCM are characterized by shorter telomeres in cardiomyocytes [142], with a correlation between hypertrophic phenotype severity and leukocyte telomere length [143]. Myosins and myosin-encoded microRNA networks may explain phenotype differences and could represent putative therapeutic targets in HCM patients [144].…”

Personalized Management of Sudden Death Risk in Primary Cardiomyopathies: From Clinical Evaluation and Multimodality Imaging to Ablation and Cardioverter-Defibrillator Implant

“…Finally, the sequencing of the entire human genome in 2003 brought a huge boost in understanding the genetic background of diseases. Nowadays, medical science is moving beyond the border of the genome towards new horizons (proteome, metabolome, and epigenome) in order to bridge the gap between genotype and phenotype [ 3 , 4 ]. Personalized medicine (PM) was defined by Horizon 2020 Advisory Group as “ a medical model using characterization of individuals’ phenotypes and genotypes for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention ” [ 5 ].…”